Last Price
5.83
Today's Change
-0.02 (0.34%)
Day's Change
5.62 - 5.90
Trading Volume
3,632,314
Market Cap
1 Billion
Shares Outstanding
235 Million
Avg Volume
3,333,792
Avg Price (50 Days)
6.08
Avg Price (200 Days)
7.09
PE Ratio
-21.59
EPS
-0.27
Earnings Announcement
29-Oct-2024
Previous Close
5.85
Open
5.90
Day's Range
5.62 - 5.9
Year Range
3.4 - 10.13
Trading Volume
3,632,314
1 Day Change
-0.34%
5 Day Change
-3.00%
1 Month Change
-1.19%
3 Month Change
6.19%
6 Month Change
-9.47%
Ytd Change
-3.64%
1 Year Change
49.10%
3 Year Change
471.57%
5 Year Change
28.98%
10 Year Change
-70.82%
Max Change
-58.68%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.